Evidence map›Paper›PMID 38876098›Full record

ArticleImmunity2024

Microbiota dictate T cell clonal selection to augment graft-versus-host disease after stem cell transplantation.

Albert C Yeh, Motoko Koyama, Olivia G Waltner, Simone A Minnie, Julie R Boiko, Tamer B Shabaneh, Shuichiro Takahashi, Ping Zhang, Kathleen S Ensbey, Christine R Schmidt and 13 more

Abstract read
In one paragraph

Article in Immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Albert C YehTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: ayeh@fredhutch.org.
Motoko KoyamaTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Olivia G WaltnerTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Simone A MinnieTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Julie R BoikoTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Tamer B ShabanehTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Shuichiro TakahashiTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Ping ZhangTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Kathleen S EnsbeyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Christine R SchmidtTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Samuel R W LeggTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Tomoko SekiguchiTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Ethan NelsonTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Shruti S BhiseTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Andrew R StevensTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Tracy GoodpasterExperimental Histopathology Core, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Saranya ChakkaTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Scott N FurlanTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Kate A MarkeyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Marie E BleakleyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Division of Hematology, Oncology, and Bone Marrow Transplantation, Department of Pediatrics, University of Washington, Seattle, WA, USA.
Charles O ElsonDepartment of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Philip H BradleyBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, USA.
Geoffrey R HillTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: grhill@fredhutch.org.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
NCCIH Supplement to NCATS/CTSA Program for KL2 Scholars - M. SoddersKL2TR002317 · NCATS · UNIVERSITY OF WASHINGTON · PI Christy Michelle McKinney · 2017 to 2026
$14.5M
CAREER DEVELOPMENT IN PEDIATRIC AND MEDICAL ONCOLOGYK12CA076930 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DAVIDSON, NANCY ELLEN, MESHINCHI, SOHEIL · 1997 to 2025
$13.1M
Preventing GVHD by inhibition of alloantigen presentation in the gutR01HL148164 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Geoffrey Roger HILL, Motoko Koyama · 2019 to 2026
$6.5M
Molecular modeling and machine learning for protein structures and interactionsR35GM141457 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2021 to 2025
$2.1M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
Propagation of graft vs. host disease through CD4+ T-cell cognate recognition of gastrointestinal microbiotaK08HL167161 · NHLBI · FRED HUTCHINSON CANCER CENTER · PI Albert Chia-Chun Yeh · 2023 to 2026
$650k
NCATS NIH HHS KL2 TR002317NCI NIH HHS K12 CA076930NCI NIH HHS P30 CA015704NHLBI NIH HHS K08 HL167161NHLBI NIH HHS R01 HL148164NIGMS NIH HHS R35 GM141457NIH HHS S10 OD028685
6 · The paper itself

Abstract

Allogeneic T cell expansion is the primary determinant of graft-versus-host disease (GVHD), and current dogma dictates that this is driven by histocompatibility antigen disparities between donor and recipient. This paradigm represents a closed genetic system within which donor T cells interact with peptide-major histocompatibility complexes (MHCs), though clonal interrogation remains challenging due to the sparseness of the T cell repertoire. We developed a Bayesian model using donor and recipient T cell receptor (TCR) frequencies in murine stem cell transplant systems to define limited common expansion of T cell clones across genetically identical donor-recipient pairs. A subset of donor CD4

Indexed as

Graft vs Host DiseaseAnimalsBayes TheoremCD4-Positive T-LymphocytesClonal Selection, Antigen-MediatedGastrointestinal MicrobiomeHematopoietic Stem Cell TransplantationMiceMice, Inbred BALB CMice, Inbred C57BLMicrobiotaReceptors, Antigen, T-CellStem Cell TransplantationTransplantation, HomologousReceptors, Antigen, T-CellCD4(+) T cellgraft-versus-host diseaseGVHDhistocompatibilitymicrobiomemicrobiota T cellsstem cell transplantT cell repertoire

Identifiers

PMID38876098
PMCPMC11236519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.